ANDAINTRAVENOUSINJECTABLE
Approved
Sep 2024
Lifecycle
Post-LOE
Competitive Pressure
30/100
Data completeness
3/8 — Basic
NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE (nicardipine hydrochloride) by Cipla is calcium channel antagonists [moa]. Approved for dihydropyridine calcium channel blocker [epc]. First approved in 2024.
Drug data last refreshed 22h ago
Mechanism of Action
Calcium Channel Antagonists
Pharmacologic Class:
Dihydropyridine Calcium Channel Blocker
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Company
Cipla
India - Mumbai
Worked on NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE at Cipla? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.